SPV-400

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders. It is taken parenterally. The preclinical pharmacokinetics of SPV-400 have been studied and described. The drug is under development by Spave Science. As of August 2025, it is in the preclinical research stage of development for neurological disorders. The chemical structure of SPV-400 does not yet appear to have been disclosed.

SPV-400 is a tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of neurological disorders. It is taken parenterally. The preclinical pharmacokinetics of SPV-400 have been studied and described. The drug is under development by Spave Science. As of August 2025, it is in the preclinical research stage of development for neurological disorders. The chemical structure of SPV-400 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1358784917 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.